Biocon Continues to be Among Science Magazine’s Top 10 Global Employers List

Ranked at No. 9 and Voted as the ‘Innovative Leader in the Industry’ for  Over a Decade

Bengaluru, Karnataka, India: October 28, 2024:

Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, has once again been ranked among the Top 10 Employers in the global biotech, pharma, and biopharma sectors by the prestigious U.S.-based Science magazine, securing No. 9 spot this year.

This ranking is for both Biocon and Biocon Biologics, since employees of both organizations participated in this survey.

The ranking reflects Biocon’s decade-long recognition as an ‘innovative leader in the industry’. Biocon’s attributes of ‘being socially responsible,’ and ‘a company with ‘loyal employees’ also adds to its attractiveness as a premier biotech employer brand.

Innovation has been a key driver of Biocon’s growth, establishing the company as a pioneer in the global biopharmaceuticals industry. Since debuting on the prestigious Science Top Employers list in 2012, Biocon has consistently featured on it, reflecting its ongoing commitment to excellence and innovation.

Kiran Mazumdar Shaw, Chairperson, Biocon Group said: “Biocon has always been R&D led, fostering a culture of ideation, experimentation, and collaboration, keeping patients at the core of its business, which has led it to be placed amongst the ‘Top 10 Global Employers’ several years in a row by Science Magazine. These attributes are appreciated by our people, who are united by the shared purpose of making affordable, high-quality medicines accessible and available to those in need, worldwide.”

This year’s ranking is based on findings from a comprehensive web-based survey of ~6,400 respondents, of whom 65% were from North America, 19% from Europe, and 11% from the Asia/Pacific Rim. About 95% of the respondents worked in biotechnology, biopharmaceutical, and pharmaceutical companies. Employees from both Biocon and Biocon Biologics participated in this survey.

About Biocon Limited: 

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com; Follow-us on X (formerly Twitter) @bioconlimited and LinkedIn: Biocon for company updates.

Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its ‘lab to market’ capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.

Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website www.bioconbiologics.com; Follow us on X (formerly Twitter): @BioconBiologics and LinkedIn: Biocon Biologics for company updates.